JP7432610B2 - 水痘帯状疱疹ウイルスを増幅または検出するための組成物および方法 - Google Patents
水痘帯状疱疹ウイルスを増幅または検出するための組成物および方法 Download PDFInfo
- Publication number
- JP7432610B2 JP7432610B2 JP2021542076A JP2021542076A JP7432610B2 JP 7432610 B2 JP7432610 B2 JP 7432610B2 JP 2021542076 A JP2021542076 A JP 2021542076A JP 2021542076 A JP2021542076 A JP 2021542076A JP 7432610 B2 JP7432610 B2 JP 7432610B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- target nucleic
- amplification primer
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 348
- 241000701085 Human alphaherpesvirus 3 Species 0.000 title claims description 220
- 238000000034 method Methods 0.000 title claims description 204
- 230000003321 amplification Effects 0.000 claims description 980
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 980
- 150000007523 nucleic acids Chemical group 0.000 claims description 800
- 239000000523 sample Substances 0.000 claims description 509
- 230000002441 reversible effect Effects 0.000 claims description 506
- 238000001514 detection method Methods 0.000 claims description 393
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 294
- 125000003729 nucleotide group Chemical group 0.000 claims description 289
- 108091034117 Oligonucleotide Proteins 0.000 claims description 223
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 135
- 239000007850 fluorescent dye Substances 0.000 claims description 40
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 16
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 15
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 12
- -1 dNTPs Substances 0.000 claims description 12
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 8
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 102100034343 Integrase Human genes 0.000 claims 4
- 239000003599 detergent Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 description 482
- 108020004707 nucleic acids Proteins 0.000 description 482
- 239000002773 nucleotide Substances 0.000 description 275
- 108091093088 Amplicon Proteins 0.000 description 221
- 238000009472 formulation Methods 0.000 description 100
- 239000011541 reaction mixture Substances 0.000 description 99
- 230000000295 complement effect Effects 0.000 description 60
- 108020004414 DNA Proteins 0.000 description 51
- 102000053602 DNA Human genes 0.000 description 51
- 238000009396 hybridization Methods 0.000 description 46
- 238000006243 chemical reaction Methods 0.000 description 40
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 39
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 38
- 229910052731 fluorine Inorganic materials 0.000 description 38
- 239000011737 fluorine Substances 0.000 description 38
- 238000003752 polymerase chain reaction Methods 0.000 description 35
- 239000003153 chemical reaction reagent Substances 0.000 description 31
- 229920002477 rna polymer Polymers 0.000 description 29
- 239000000047 product Substances 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 25
- 230000004048 modification Effects 0.000 description 25
- 238000012986 modification Methods 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 23
- 229910001629 magnesium chloride Inorganic materials 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 19
- 108091033319 polynucleotide Proteins 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 19
- 238000003753 real-time PCR Methods 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 241000700605 Viruses Species 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- 238000005382 thermal cycling Methods 0.000 description 11
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 10
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 10
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 10
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 9
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 9
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 9
- 102100031780 Endonuclease Human genes 0.000 description 9
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 9
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 8
- 108091092584 GDNA Proteins 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108020004682 Single-Stranded DNA Proteins 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 108091028664 Ribonucleotide Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000007848 endpoint PCR Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 229910017053 inorganic salt Inorganic materials 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011897 real-time detection Methods 0.000 description 4
- 239000002336 ribonucleotide Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 201000006082 Chickenpox Diseases 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 206010046980 Varicella Diseases 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000005546 dideoxynucleotide Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000011880 melting curve analysis Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 150000003212 purines Chemical class 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 150000002972 pentoses Chemical class 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000006163 transport media Substances 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 208000035742 Air-borne transmission Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 101150059079 EBNA1 gene Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000005557 airborne transmission Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024015567A JP7693035B2 (ja) | 2018-10-01 | 2024-02-05 | 水痘帯状疱疹ウイルスを増幅または検出するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739571P | 2018-10-01 | 2018-10-01 | |
| US62/739,571 | 2018-10-01 | ||
| PCT/US2019/053943 WO2020072409A1 (en) | 2018-10-01 | 2019-10-01 | Compositions and methods for amplifying or detecting varicella-zoster virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024015567A Division JP7693035B2 (ja) | 2018-10-01 | 2024-02-05 | 水痘帯状疱疹ウイルスを増幅または検出するための組成物および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022501073A JP2022501073A (ja) | 2022-01-06 |
| JPWO2020072409A5 JPWO2020072409A5 (https=) | 2022-10-11 |
| JP2022501073A5 JP2022501073A5 (https=) | 2022-10-11 |
| JP7432610B2 true JP7432610B2 (ja) | 2024-02-16 |
Family
ID=68296720
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542076A Active JP7432610B2 (ja) | 2018-10-01 | 2019-10-01 | 水痘帯状疱疹ウイルスを増幅または検出するための組成物および方法 |
| JP2024015567A Active JP7693035B2 (ja) | 2018-10-01 | 2024-02-05 | 水痘帯状疱疹ウイルスを増幅または検出するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024015567A Active JP7693035B2 (ja) | 2018-10-01 | 2024-02-05 | 水痘帯状疱疹ウイルスを増幅または検出するための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12460272B2 (https=) |
| EP (2) | EP3861141B1 (https=) |
| JP (2) | JP7432610B2 (https=) |
| AU (1) | AU2019351824B2 (https=) |
| WO (1) | WO2020072409A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114790494B (zh) * | 2021-11-04 | 2024-03-22 | 江汉大学 | 一种水痘-带状疱疹病毒的mnp标记位点、引物组合物、试剂盒及其应用 |
| CN115807126A (zh) * | 2022-09-22 | 2023-03-17 | 江苏博嘉生物医学科技有限公司 | 一种水痘-带状疱疹病毒的检测试剂盒及检测方法 |
| CN119570984A (zh) * | 2024-12-20 | 2025-03-07 | 江苏省疾病预防控制中心(江苏省预防医学科学院) | 水痘-带状疱疹病毒全基因组捕获方法、引物组及试剂盒 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101871013A (zh) | 2009-04-22 | 2010-10-27 | 中山大学达安基因股份有限公司 | 检测水痘-带状疱疹病毒的试剂盒 |
| CN103866046A (zh) | 2014-01-21 | 2014-06-18 | 浙江大学 | 人疱疹病毒ebv和vzv检测试剂盒 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2422956A1 (fr) | 1978-04-13 | 1979-11-09 | Pasteur Institut | Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede |
| US4786600A (en) | 1984-05-25 | 1988-11-22 | The Trustees Of Columbia University In The City Of New York | Autocatalytic replication of recombinant RNA |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5541308A (en) | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5283174A (en) | 1987-09-21 | 1994-02-01 | Gen-Probe, Incorporated | Homogenous protection assay |
| US5118801A (en) | 1988-09-30 | 1992-06-02 | The Public Health Research Institute | Nucleic acid process containing improved molecular switch |
| US5656207A (en) | 1989-06-24 | 1997-08-12 | Gen Probe Incorporated | Detecting or quantifying multiple analytes using labelling techniques |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| US5427930A (en) | 1990-01-26 | 1995-06-27 | Abbott Laboratories | Amplification of target nucleic acids using gap filling ligase chain reaction |
| US5516663A (en) | 1990-01-26 | 1996-05-14 | Abbott Laboratories | Ligase chain reaction with endonuclease IV correction and contamination control |
| US5422252A (en) | 1993-06-04 | 1995-06-06 | Becton, Dickinson And Company | Simultaneous amplification of multiple targets |
| US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5547861A (en) | 1994-04-18 | 1996-08-20 | Becton, Dickinson And Company | Detection of nucleic acid amplification |
| US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
| US6169169B1 (en) | 1994-05-19 | 2001-01-02 | Dako A/S | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
| EP0709466B1 (en) | 1994-10-28 | 2006-09-27 | Gen-Probe Incorporated | Compositions and methods for the simultaneous detection and quantification of multiple specific nucleic acid sequences |
| US5801155A (en) | 1995-04-03 | 1998-09-01 | Epoch Pharmaceuticals, Inc. | Covalently linked oligonucleotide minor grove binder conjugates |
| US5731148A (en) | 1995-06-07 | 1998-03-24 | Gen-Probe Incorporated | Adduct protection assay |
| DE69836012T2 (de) | 1997-05-02 | 2007-04-05 | Gen-Probe Inc., San Diego | Zwei-schritt hybridisierung und einfang von einem polynukleotid |
| US6071745A (en) | 1997-06-27 | 2000-06-06 | Bio-Rad Laboratories | Method and formulation for lyophilizing cultured human cells to preserve RNA and DNA contained in cells for use in molecular biology experiments |
| US6180340B1 (en) | 1997-10-31 | 2001-01-30 | Gen-Probe Incorporated | Extended dynamic range assays |
| ES2330812T3 (es) | 1998-07-02 | 2009-12-15 | Gen-Probe Incorporated | Antorchas moleculares. |
| US6849407B2 (en) * | 2000-08-31 | 2005-02-01 | Mayo Foundation For Medical Education And Research | Detection of varicella-zoster virus |
| DE60200248T2 (de) | 2002-08-01 | 2005-01-27 | Mtm Laboratories Ag | Verfahren für Lösung-basierte Diagnose |
| CA2898814C (en) | 2004-08-27 | 2015-12-29 | Gen-Probe Incorporated | Single-primer nucleic acid amplification methods |
| EP1945821B1 (en) | 2006-06-06 | 2011-01-19 | Gen-Probe Incorporated | Tagged oligonucleotides and their use in nucleic acid amplification methods |
| US9051601B2 (en) | 2006-08-01 | 2015-06-09 | Gen-Probe Incorporated | Methods of nonspecific target capture of nucleic acids |
| CN102140543B (zh) * | 2011-03-11 | 2013-06-19 | 中山大学 | 鉴定发热伴出疹症候群传染病相关病毒病原体的多重实时定量pcr的引物、探针及检测方法 |
| CN105132584B (zh) | 2015-08-03 | 2018-06-29 | 中国人民解放军成都军区总医院 | 用于分型检测水痘带状疱疹病毒的试剂盒及其生产方法与应用 |
| WO2017040316A1 (en) * | 2015-08-28 | 2017-03-09 | The Broad Institute, Inc. | Sample analysis, presence determination of a target sequence |
-
2019
- 2019-10-01 US US17/281,543 patent/US12460272B2/en active Active
- 2019-10-01 EP EP19790990.6A patent/EP3861141B1/en active Active
- 2019-10-01 EP EP25157649.2A patent/EP4538394A3/en active Pending
- 2019-10-01 JP JP2021542076A patent/JP7432610B2/ja active Active
- 2019-10-01 AU AU2019351824A patent/AU2019351824B2/en active Active
- 2019-10-01 WO PCT/US2019/053943 patent/WO2020072409A1/en not_active Ceased
-
2024
- 2024-02-05 JP JP2024015567A patent/JP7693035B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101871013A (zh) | 2009-04-22 | 2010-10-27 | 中山大学达安基因股份有限公司 | 检测水痘-带状疱疹病毒的试剂盒 |
| CN103866046A (zh) | 2014-01-21 | 2014-06-18 | 浙江大学 | 人疱疹病毒ebv和vzv检测试剂盒 |
Non-Patent Citations (2)
| Title |
|---|
| MATSUSHIMA et al.，Microbiology and Immunology，2017年，Vol. 61, No. 8，p.337-344，DOI: 10.1111/1348-0421.12502 |
| TANAKA et al.，Biomedical Research，2009年，Vol. 30, No. 5，p.279-285，DOI: 10.2220/biomedres.30.279 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020072409A8 (en) | 2020-05-28 |
| JP7693035B2 (ja) | 2025-06-16 |
| EP4538394A2 (en) | 2025-04-16 |
| EP3861141B1 (en) | 2026-03-11 |
| EP3861141A1 (en) | 2021-08-11 |
| US12460272B2 (en) | 2025-11-04 |
| JP2024032995A (ja) | 2024-03-12 |
| WO2020072409A1 (en) | 2020-04-09 |
| AU2019351824B2 (en) | 2025-08-14 |
| EP4538394A3 (en) | 2025-10-08 |
| JP2022501073A (ja) | 2022-01-06 |
| CA3112342A1 (en) | 2020-04-09 |
| US20220017980A1 (en) | 2022-01-20 |
| AU2019351824A1 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210189469A1 (en) | Probes for improved melt discrimination and multiplexing in nucleic acid assays | |
| JP7693035B2 (ja) | 水痘帯状疱疹ウイルスを増幅または検出するための組成物および方法 | |
| JP7531535B2 (ja) | 試料中のウイルス病原体を検出するための組成物および方法 | |
| CN108588279A (zh) | Hev测定 | |
| JP7788434B2 (ja) | アデノウイルス、メタニューモウイルス、および／またはライノウイルス核酸を検出するための組成物、方法、およびキット | |
| CA3112342C (en) | Compositions and methods for amplifying or detecting varicella-zoster virus | |
| JP7542546B2 (ja) | ヒトポリオーマウイルスｂｋウイルスを増幅、検出または定量化するための組成物および方法 | |
| US20230082096A1 (en) | Compositions and methods for detecting coronavirus nucleic acid | |
| JP4874999B2 (ja) | Ｂ群連鎖球菌属を検出するための組成物及び方法 | |
| EP4565720A1 (en) | Assays for detecting monkeypox virus | |
| EP4337797A1 (en) | Compositions and methods for detecting human adenovirus nucleic acid | |
| HK40047605A (en) | Compositions and methods for amplifying, detecting or quantifying human polyomavirus bk virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220930 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220930 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230814 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231107 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240104 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7432610 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |